Antibody Therapy Targeting CD47 and CD271 Effectively Suppresses Melanoma Metastasis in Patient-Derived Xenografts
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
The high rate of metastasis and recurrence among melanoma patients indicates the existence of cells within melanoma that have the ability to both initiate metastatic programs and bypass immune recognition. Here, we identify CD47 as a regulator of melanoma tumor metastasis and immune evasion. Protein and gene expression analysis of clinical melanoma samples reveals that CD47, an anti-phagocytic signal, correlates with melanoma metastasis. Antibody-mediated blockade of CD47 coupled with targeting of CD271(+) melanoma cells strongly inhibits tumor metastasis in patient-derived xenografts. This therapeutic effect is mediated by drastic changes in the tumor and metastatic site immune microenvironments, both of whichwhich exhibit greatly increased density of differentiated macrophages and significantly fewer inflammatory monocytes, pro-metastatic macrophages (CCR2(+)/VEGFR1(+)), and neutrophils, all of which are associated with disease progression. Thus, antibody therapy that activates the innate immune response in combination with selective targeting of CD271(+) melanoma cells represents a powerful therapeutic approach against metastatic melanoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860
The M1 and M2 paradigm of macrophage activation: Time for reassessment
Martinez, F. O., & Gordon, S. (2014) · F1000Prime Reports · doi:10.12703/p6-13 · Cited by 4,689 · cited 2×
“…distinct M1/M2 subtypes based on established patterns of gene expression needs to be approached with caution, and depends in each case on the homeostatic and pathological conditions of the living tissue from which the macrophages are being sampled (Franklin et al., 2014; Martinez and Gordon, 2014).”
Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm
Biswas, S. K., & Mantovani, A. (2010) · Nature Immunology · doi:10.1038/ni.1937 · Cited by 3,840 · cited 2×
“In cancer patients, macrophages elicit their activity by binding to and phagocytosing malignant cells, contributing to reduced tumor growth (Biswas and Mantovani, 2010).”
CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis
Qian, B.-Z., Li, J., Zhang, H., Kitamura, T., Zhang, J., Campion, L. R., Kaiser, E. A., Snyder, L. A., & Pollard, J. W. (2011) · Nature · doi:10.1038/nature10138 · Cited by 2,874 · cited 7×
“1 C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). vascular endothelial growth factor receptor 1 (VEGFR1) (Qian et al., 2011; Ren et al., 2012).”
InfluentialNivolumab and ipilimumab versus ipilimumab in untreated melanoma
Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414428 · Cited by 2,781
Cancer regression in patients after transfer of genetically engineered lymphocytes
Morgan, R. A., Dudley, M. E., Wunderlich, J. R., Hughes, M. S., Yang, J. C., Sherry, R. M., Royal, R. E., Topalian, S. L., Kammula, U. S., Restifo, N. P., et al. (2006) · Science · doi:10.1126/science.1129003 · Cited by 2,603 · cited 1×
“…combination of cell-surface markers specific for the following populations: inflammatory monocytes (Lin , CD11blo, CD11c , F4/80 , (legend continued on next page) Cell Reports 16, 1–16, August 9, 2016 13 NY-ESO-1 (Cormier et al., 1997; Dudley et al., 2001; Morgan et al., 2006; O’Neil et al., 1993).”
Schadendorf, D., Hodi, F. S., Robert, C., Weber, J. S., Margolin, K., Hamid, O., Patt, D., Chen, T.-T., Berman, D. M., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2736 · Cited by 2,141 · cited 2×
“0 months), with a 3-year survival rate of only 21% (95% CI, 20%–22%) (Schadendorf et al., 2015).”
Monocytes and macrophages: developmental pathways and tissue homeostasis
Ginhoux, F., & Jung, S. (2014) · Nature Reviews Immunology · doi:10.1038/nri3671 · Cited by 1,840 · cited 2×
“…due to injury or inflammation (also hallmarks of tumor growth), Ly6Chi/C-C chemokine receptor (CCR)2+ monocytes are rapidly recruited to these sites, where they extravasate and differentiate into macrophages and certain types of dendritic cells (Ginhoux and Jung, 2014; Serbina and Pamer, 2006).”
Understanding the Mysterious M2 Macrophage through Activation Markers and Effector Mechanisms
Rőszer, T. (2015) · Mediators of Inflammation · doi:10.1155/2015/816460 · Cited by 1,762 · cited 1×
“Expression of genes that include Mrc1 (CD206), Fizz1, Ym1, Mgl1 (CD301a), Arg1, Nos2, and Il10 has commonly been used to classify macrophage populations into the M1 and M2 (M2a–M2c) subgroups (Qian and Pollard, 2010; Roszer, 2015).”
Majeti, R., Chao, M. P., Alizadeh, A. A., Pang, W. W., Jaiswal, S., Gibbs, K. D., van Rooijen, N., & Weissman, I. L. (2009) · Cell · doi:10.1016/j.cell.2009.05.045 · Cited by 1,752 · cited 4×
“Recent studies found that masking CD47 with anti-CD47monoclonal antibodies on the surface of hematopoietic and epithelial cancer cells leads to stimulation of phagocytosis in vitro and decreased tumor burden in vivo (Jaiswal et al., 2009;Majeti et al., 2009;Willingham et al., 2012).”
InfluentialSelf-citation
Cited by
Engineering Macrophages for Cancer Immunotherapy and Drug Delivery
Xia, Y., Rao, L., Yao, H., Wang, Z., Ning, P., & Chen, X. (2020) · Advanced Materials · doi:10.1002/adma.202002054 · Cited by 949
Phagocytosis checkpoints as new targets for cancer immunotherapy
Feng, M., Jiang, W., Kim, B. Y. S., Zhang, C. C., Fu, Y.-X., & Weissman, I. L. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0183-z · Cited by 911
Self-citationCancer immunotherapy targeting the CD47/SIRPα axis
Weiskopf, K. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.02.013 · Cited by 353
Self-citationLequeux, A., Noman, M. Z., Xiao, M., Sauvage, D., Van Moer, K., Viry, E., Bocci, I., Hasmim, M., Bosseler, M., Berchem, G., et al. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.05.021 · Cited by 117
Regulation of senescence escape by TSP1 and CD47 following chemotherapy treatment
Guillon, J., Petit, C., Moreau, M., Toutain, B., Henry, C., Roché, H., Bonichon-Lamichhane, N., Salmon, J. P., Lemonnier, J., Campone, M., et al. (2019) · Cell Death & Disease · doi:10.1038/s41419-019-1406-7 · Cited by 90
Metadata
- Authors
- Ngo, M., Han, A., Lakatos, A., Sahoo, D., Hachey, S. J., Weiskopf, K., Beck, A. H., Weissman, I. L., & Boiko, A. D.
- Venue
- Cell Reports
- Publisher
- Elsevier BV
- Published
- 2016-08
- Volume
- 16
- Issue
- 6
- Pages
- 1701-1716
- ISSN
- 2211-1247 (ISSN-L)
- OpenAlex
- W2500279326
- Cited by
- 74
- References
- 15
- FWCI
- 5.38
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antibody Therapy Targeting CD47 and CD271 Effectively Suppresses Melanoma Metastasis in Patient-Derived Xenografts. https://app.cochat.ai/papers/10.1016/j.celrep.2016.07.004
- The paper
- Ngo, M., Han, A., Lakatos, A., Sahoo, D., Hachey, S. J., Weiskopf, K., Beck, A. H., Weissman, I. L., & Boiko, A. D. (2016). Antibody Therapy Targeting CD47 and CD271 Effectively Suppresses Melanoma Metastasis in Patient-Derived Xenografts. Cell Reports. https://doi.org/10.1016/j.celrep.2016.07.004
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.